t, indicate, or imply future
results, performance or achievements, and may contain the words "estimate,"
"project," "intend," "forecast," "anticipate," "plan," "planning,"
"expect," "believe," "will," "will likely," "should," "could," "would,"
"may" or words or expressions of similar meaning. All such forward-looking
statements involve risks and uncertainties, including, but not limited to:
statements regarding the Company's products; marketing and sales; patents
and regulatory approvals; the effect of competition and proprietary rights
of third parties; the need for and availability of additional financing and
access to capital; the seeking of joint development, licensing or
distribution and collaboration and marketing arrangements with other
companies. There can be no assurance that such forward-looking statements
will prove to be accurate and Yongye undertakes no obligation to update any
forward-looking statements or to announce revisions to any of the
For more information, please contact:
Yongye Biotechnology International, Inc.
Mr. Larry Gilmore-VP of Corporate Strategy
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Page: 1 2 3 Related biology technology :1
|SOURCE Yongye Biotechnology International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Yongye Biotechnology International Announces Second Quarter Results2
. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results3
. Yongye Biotechnology International Retains CCG Investor Relations4
. Yongye Biotechnology International, Inc. Appoints New Independent Auditor5
. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing6
. InNexus Biotechnology Strengthens Patent Team With New Leadership7
. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC8
. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation9
. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance10
. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products11
. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents